{"gene":"EGFR","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1998,"finding":"ErbB1 (EGFR) acquires distinct signaling properties depending on its dimerization partner: EGF-activated ErbB-1 interacts with Grb2 and undergoes rapid internalization with biphasic PI3-K association, whereas NDF-activated ErbB-1 (via ErbB-4 heterodimerization) cannot interact with Grb2 and shows delayed internalization with monophasic PI3-K association. Tryptic phosphopeptide mapping confirmed that receptor phosphorylation patterns are dependent on the dimerization partner.","method":"Co-immunoprecipitation, phosphopeptide mapping, internalization assays in NIH 3T3 cells expressing defined receptor combinations","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, phosphopeptide mapping, and internalization assays; multiple orthogonal methods in a single focused study","pmids":["9710588"],"is_preprint":false},{"year":1998,"finding":"At high concentrations, EGF and betacellulin can activate the ErbB-2/ErbB-3 heterodimer as a surrogate receptor in the absence of ErbB-1; the middle portion of EGF (loop B) was identified as the structural determinant enabling activation of the ErbB-2/ErbB-3 complex.","method":"Cell growth/differentiation assays with site-specific antibody blockade, EGF/TGFα chimera analysis in cells expressing defined receptor combinations","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (antibody blockade, chimeric ligand mapping, defined receptor expression systems) in a single study","pmids":["9546426"],"is_preprint":false},{"year":2003,"finding":"EGFR (ErbB1) trafficking is uniquely ligand-regulated among ErbB family members: upon EGF binding, EGFR undergoes accelerated internalization and enhanced lysosomal targeting (rather than recycling), mediated by cytoplasmic domain motifs exposed by activation-induced conformational changes and Grb2 binding. Most EGFR signaling consequently occurs within endosomes.","method":"Receptor trafficking assays, receptor internalization rate measurements, domain mutant analysis, Grb2-binding studies","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection of trafficking motifs and Grb2 involvement, primarily review synthesizing experimental data from multiple labs","pmids":["12648467"],"is_preprint":false},{"year":2006,"finding":"UBPY (Usp8) constitutively co-precipitates with EGFR in a bivalent manner and is a substrate for Src-family tyrosine kinases activated by ligand-induced EGFR activation. Dominant-negative UBPY mutants demonstrate that UBPY-mediated deubiquitination promotes (rather than inhibits) EGFR degradation, and affects both constitutive and ligand-induced EGFR ubiquitination, expression levels, and MAPK signaling.","method":"Co-immunoprecipitation, dominant-negative UBPY mutant overexpression, ubiquitination assays in NIH3T3 and HEK293 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus multiple dominant-negative mutants (three independent constructs), single lab","pmids":["17121848"],"is_preprint":false},{"year":2008,"finding":"EGFR (ErbB1) can undergo metalloprotease-dependent ectodomain shedding to generate soluble N-terminal ectodomains (which retain ligand-binding ability) and membrane-associated C-terminal remnant fragments; full-length transmembrane ErbB1 is also secreted in exosomes. Ligand-stimulated ErbB1 secretion into exosomes requires ErbB1 kinase activity, as it is blocked by the kinase inhibitor AG1478.","method":"Exosome isolation, metalloprotease inhibitor treatments (GM6001), kinase inhibitor (AG1478) treatment, Western blotting of conditioned medium fractions","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical fractionation with pharmacological inhibitors, single lab, two orthogonal methods","pmids":["17910038"],"is_preprint":false},{"year":2008,"finding":"ARAP1 (an Arf GAP/Rho GAP domain protein) regulates EGFR endocytic trafficking: after EGF treatment, ARAP1 transiently associates with Rab5-positive punctate structures containing EGFR prior to EEA1-positive early endosomes; ARAP1 recruitment requires active Rab5 and a signal from EGFR. siRNA knockdown of ARAP1 accelerated EGFR association with EEA1 endosomes and EGFR degradation, and diminished ERK and JNK phosphorylation.","method":"siRNA knockdown, fluorescence microscopy, co-localization with endosomal markers, ERK/JNK phosphorylation assays","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with defined cellular phenotype, co-localization microscopy, signaling readouts; single lab","pmids":["18939958"],"is_preprint":false},{"year":2010,"finding":"Cytohesin family proteins are cytoplasmic activators of ErbB receptors including EGFR: cytohesin inhibition decreased EGFR autophosphorylation and downstream signaling, while cytohesin overexpression stimulated receptor activation. Cell-free reconstitution of cytohesin-dependent EGFR autophosphorylation and anisotropy microscopy monitoring of EGFR conformation indicated cytohesins facilitate conformational rearrangements in intracellular domains of dimerized receptors.","method":"Cell-free reconstitution assay, anisotropy microscopy (EGFR conformation monitoring), cytohesin overexpression/inhibition, in vitro and in vivo proliferation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-free reconstitution plus anisotropy microscopy and in vivo validation; multiple orthogonal methods in a single rigorous study","pmids":["20946980"],"is_preprint":false},{"year":2011,"finding":"ErbB1 (EGFR) dimerization is promoted by transient co-confinement of receptors and stabilized by ligand binding: two-color quantum-dot tracking revealed that dimers of two ligand-bound receptors are long-lived (>4-fold slower dimer off-rate than unliganded dimers) and dimer off-rate is independent of kinase activity. Blockade of kinase activity or disruption of actin networks results in faster diffusion of receptor dimers, implicating cortical cytoskeleton in reduced mobility of signaling-competent dimers.","method":"Two-color quantum-dot single-particle tracking, hidden Markov model analysis of dimer kinetics, kinase inhibitors, actin network disruption in living cells","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative single-molecule live-cell imaging with rigorous kinetic modeling and pharmacological validation, multiple orthogonal perturbations","pmids":["22020299"],"is_preprint":false},{"year":2013,"finding":"DYRK1A kinase regulates EGFR stability in glioblastoma: DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, reducing self-renewal capacity. This establishes DYRK1A as a positive regulator of surface EGFR levels, and DYRK1A-dependent EGFR stabilization as a key oncogenic mechanism in a subset of GBMs.","method":"DYRK1A pharmacological inhibition, EGFR degradation assays, primary GBM cell lines, in vivo tumor burden assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with cellular and in vivo phenotype, single lab, multiple readouts","pmids":["23635774"],"is_preprint":false},{"year":2018,"finding":"EGFR (ERBB1) activity is required for KRAS-driven lung tumor initiation and progression: multiple ERBB RTKs are expressed and active from the earliest stages of KRASG12D-driven lung tumor development, and multi-ERBB inhibition suppresses formation of these tumors. ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells.","method":"Autochthonous mouse lung tumor model (KRASG12D), multi-ERBB inhibitor treatment, MEK inhibitor combination, in vitro proliferation assays","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in autochthonous mouse model plus in vitro signaling studies; single lab with multiple experimental approaches","pmids":["29925636"],"is_preprint":false},{"year":2021,"finding":"FBXL2 (an F-box protein) targets EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation. Grp94 protects EGFR from FBXL2-mediated degradation by blocking FBXL2 binding to EGFR. The FBXL2-Grp94-EGFR axis controls EGFR protein stability in NSCLC.","method":"Co-immunoprecipitation, proteasome inhibitor assays, FBXL2 knockdown/overexpression, Grp94 inhibition, in vitro and in vivo NSCLC growth assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP establishing FBXL2-EGFR and Grp94-EGFR interactions, proteasomal degradation assays, in vivo validation; multiple orthogonal methods","pmids":["34635651"],"is_preprint":false},{"year":2018,"finding":"USP22 deubiquitinates EGFR localized on late endosomes, prevents ubiquitination-mediated EGFR degradation, and enhances EGFR recycling after EGF stimulation, thereby sustaining activation of EGFR downstream signaling pathways (STAT3, AKT/mTOR, MEK/ERK) and promoting resistance to EGFR-TKIs.","method":"USP22 knockdown/overexpression, ubiquitination assays, EGFR degradation and recycling assays, downstream signaling analysis, in vitro and in vivo resistance assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic deubiquitination assay with trafficking and signaling readouts; single lab, multiple methods","pmids":["29981430"],"is_preprint":false},{"year":2015,"finding":"The plasma membrane sialidase NEU3 co-immunoprecipitates with EGFR and, when catalytically active, enhances EGFR activation (phosphorylation) without affecting EGFR mRNA or protein expression levels. Active NEU3 desialylates immunoprecipitated EGFR, as confirmed by Western blot and mass spectrometry, suggesting EGFR sialylation status modulates its activation.","method":"Co-immunoprecipitation, overexpression of wild-type vs. catalytically inactive NEU3 mutant, Western blot, mass spectrometry of EGFR glycosylation","journal":"Glycobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus mass spectrometry-confirmed desialylation, wild-type vs. inactive mutant comparison; single lab","pmids":["25922362"],"is_preprint":false},{"year":2003,"finding":"Wnt1 and Wnt5a transactivate ErbB1 (EGFR) in HC11 mammary epithelial cells via metalloprotease-mediated release of soluble ErbB1 ligands downstream of Frizzled receptor activation. ErbB1 transactivation by Wnt was required for MAPK activation and cyclin D1 upregulation in Wnt-expressing cells.","method":"Conditioned medium transfer assays, ErbB1-blocking antibody, MMP inhibitors, MAPK and cyclin D1 measurements in HC11 cells","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody blockade and MMP inhibitor rescue experiments establish pathway epistasis; single lab, multiple inhibitor approaches","pmids":["12612606"],"is_preprint":false},{"year":2004,"finding":"ErbB-1 (EGFR) kinase activity is essential for androgen-induced proliferation and survival of LNCaP prostate cancer cells: androgens increase ErbB1 surface levels while decreasing ErbB2 levels, and ErbB1 kinase inhibitors (CGP59326, PKI166) completely block androgen-induced proliferation and prevent androgen-mediated rescue from PI3K inhibitor-induced apoptosis.","method":"ErbB1 tyrosine kinase inhibitors (CGP59326, PKI166), LNCaP cell proliferation and apoptosis assays, Western blotting of receptor levels","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with proliferation and apoptosis phenotype; single lab, two inhibitors tested","pmids":["12746839"],"is_preprint":false},{"year":2009,"finding":"ERBB1 (EGFR) inhibition specifically blocks tumor cell motility and invasion in vivo, while ERBB2 inhibition specifically blocks intravasation, distinguishing the contributions of each receptor to distinct steps of metastasis. ERBB1 inhibition (gefitinib) rapidly (within 3 h) inhibits invasion but not intravasation, whereas ERBB2 inhibition blocks intravasation.","method":"In vivo mouse mammary tumor models, intravital imaging of tumor cell motility and intravasation, selective small-molecule inhibitors (gefitinib for ERBB1, AG825 for ERBB2)","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo intravital imaging with selective inhibitors distinguishing EGFR vs ERBB2 roles; single lab","pmids":["19458057"],"is_preprint":false},{"year":2022,"finding":"Constitutive (ligand-independent) EGFR signaling promotes glioblastoma invasion via a TAB1-TAK1-NF-κB-EMP1 pathway, while ligand-activated EGFR suppresses invasion by upregulating BIN3, which inhibits a DOCK7-regulated Rho GTPase pathway. Ligand binding thus shifts EGFR from an invasion-promoting to an invasion-suppressing role in EGFR-amplified GBM.","method":"Orthotopic mouse GBM models, pathway-specific knockdowns, in vitro invasion assays, BIN3/DOCK7 pathway analysis, TCGA data correlation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo orthotopic models with mechanistic pathway dissection, multiple genetic perturbations, and clinical data correlation; multiple orthogonal methods","pmids":["35915159"],"is_preprint":false},{"year":2004,"finding":"Glial erbB-1 and erbB-4 receptors work in a coordinated fashion to control LHRH secretion and reproductive function: double-mutant mice (Waved-2 erbB-1 point mutation plus dominant-negative erbB-4 in astrocytes) show further delayed puberty and diminished reproductive capacity compared to single mutants. Mutant astrocytes fail to produce prostaglandin E2 in response to TGFα, and conditioned medium from mutant astrocytes fails to stimulate LHRH release.","method":"Genetic epistasis (double-mutant mouse crosses), astrocyte prostaglandin E2 production assays, LHRH release assay from GT1-7 cells, LH response to ovariectomy","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic double-mutant epistasis with cellular mechanistic readouts; single publication","pmids":["15591145"],"is_preprint":false},{"year":2008,"finding":"Cardiac ErbB-1 (EGFR) signaling is required for adult cardiac function: cardiomyocyte-specific expression of dominant-negative ErbB-1 mutant blocked endogenous ErbB-1 phosphorylation and ErbB-2 transphosphorylation, leading to cardiac hypertrophy, dilation, and dysfunction (decreased fractional shortening). Cardiac function was normalized by adenylyl cyclase activator treatment and reversed upon cessation of mutant expression.","method":"Ecdysone-inducible cardiomyocyte-specific dominant-negative ErbB-1 mutant expression, echocardiography, histology, Western blotting of receptor phosphorylation","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible dominant-negative in vivo mouse model with molecular and physiological readouts; single lab","pmids":["18599591"],"is_preprint":false},{"year":2013,"finding":"ErbB1-integrin-β1 physical heteroassociation (measured by FRET) in glioblastoma correlates with radioresistance: ectopic ErbB1 expression upregulated integrin-β1 and increased ErbB1-integrin-β1 heteroassociation, boosting Akt phosphorylation in response to EGF. Radioresistance could be reverted by PI3K inhibition, establishing ErbB1-integrin-β1 interaction as a driver of Akt-mediated radioresistance.","method":"Acceptor photobleaching FRET on clinical frozen sections and in vitro glioma cell lines, ErbB1 ectopic expression, PI3K inhibitor rescue, Akt phosphorylation assays","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET-based direct interaction measurement plus functional rescue with PI3K inhibitor; single lab","pmids":["23595626"],"is_preprint":false}],"current_model":"EGFR (ErbB1) is a ligand-activated receptor tyrosine kinase whose activity, signaling output, and fate are controlled by a multilayered network: ligand binding drives homo- or heterodimerization (with distinct dimer-dependent phosphorylation patterns and signaling properties), cytoplasmic conformational activators (cytohesins) facilitate kinase domain activation, ligand-occupied dimers are stabilized by co-confinement and cortical actin interactions, activated receptor undergoes accelerated clathrin-mediated internalization and lysosomal targeting (regulated by ubiquitination/deubiquitination via UBPY/USP22/FBXL2-Grp94 and trafficking regulators such as ARAP1), and constitutive vs. ligand-activated EGFR signaling can engage distinct downstream pathways (e.g., TAB1-TAK1-NF-κB-EMP1 for invasion vs. BIN3-DOCK7 for invasion suppression), with additional modulation by sialylation state, transactivation by GPCRs and Wnt via metalloprotease-dependent ligand shedding, and stabilization/destabilization by kinases such as DYRK1A."},"narrative":{"mechanistic_narrative":"EGFR (ErbB1) is a ligand-activated receptor tyrosine kinase whose signaling output, trafficking, and physiological fate are shaped by its dimerization state, conformational regulators, and the route by which it is internalized and degraded [PMID:9710588, PMID:20946980]. Ligand binding determines both partner choice and downstream wiring: EGF-activated ErbB1 binds Grb2 and internalizes rapidly with biphasic PI3-K association, whereas heterodimerization with ErbB-4 yields a Grb2-incompetent receptor with delayed internalization and distinct phosphopeptide patterns [PMID:9710588], and high-affinity ligands can drive ErbB-2/ErbB-3 surrogate signaling in the absence of ErbB1 [PMID:9546426]. Receptor activation is facilitated by cytoplasmic cytohesins, which promote conformational rearrangement of the intracellular domains of dimerized receptors to enable autophosphorylation [PMID:20946980], while signaling-competent dimers of two ligand-bound receptors are long-lived and stabilized by co-confinement and cortical actin [PMID:22020299]. Activated EGFR is uniquely routed toward accelerated clathrin-mediated internalization and lysosomal degradation rather than recycling, so much of its signaling occurs from endosomes [PMID:12648467]; this fate is tuned by trafficking and degradation machinery including ARAP1 at Rab5 endosomes [PMID:18939958], the deubiquitinases UBPY/USP8 and USP22 [PMID:17121848, PMID:29981430], the FBXL2–Grp94 axis controlling proteasomal stability [PMID:34635651], and the stabilizing kinase DYRK1A [PMID:23635774]. Additional input comes from NEU3-mediated desialylation, which enhances EGFR phosphorylation without changing its expression [PMID:25922362], and from transactivation by Wnt and other stimuli through metalloprotease-dependent shedding of soluble ligands [PMID:12612606]. EGFR activity drives proliferation, survival, motility, and invasion across multiple tissue and tumor contexts, including KRAS-driven lung tumor initiation [PMID:29925636], androgen-dependent prostate cancer growth [PMID:12746839], and metastatic cell motility [PMID:19458057]; in EGFR-amplified glioblastoma, constitutive signaling promotes invasion via TAB1-TAK1-NF-κB-EMP1 whereas ligand-activated EGFR suppresses invasion via BIN3-DOCK7 [PMID:35915159]. EGFR also supports normal physiology, including astrocyte-mediated control of LHRH secretion [PMID:15591145] and adult cardiac function [PMID:18599591].","teleology":[{"year":1998,"claim":"Established that EGFR signaling identity is dimerization-partner-dependent rather than fixed, explaining how the same receptor produces divergent outputs.","evidence":"Co-IP, phosphopeptide mapping, and internalization assays in NIH 3T3 cells with defined receptor combinations; plus chimeric-ligand mapping of ErbB-2/ErbB-3 surrogate activation","pmids":["9710588","9546426"],"confidence":"High","gaps":["Structural basis of dimer-specific phosphosite selection not resolved","Physiological ligand concentrations for surrogate ErbB-2/ErbB-3 activation unclear"]},{"year":2003,"claim":"Defined EGFR as uniquely ligand-routed to lysosomal degradation, reframing endosomes as a principal signaling compartment.","evidence":"Trafficking and internalization-rate assays, cytoplasmic-domain mutant analysis, and Grb2-binding studies (review synthesizing experimental data)","pmids":["12648467"],"confidence":"Medium","gaps":["Quantitative contribution of endosomal vs surface signaling not partitioned","Review-level synthesis rather than single primary dataset"]},{"year":2003,"claim":"Showed EGFR can be transactivated by Wnt through metalloprotease-dependent ligand shedding, linking it to non-canonical upstream inputs.","evidence":"Conditioned-medium transfer, ErbB1-blocking antibody, and MMP inhibitors with MAPK/cyclin D1 readouts in HC11 mammary cells","pmids":["12612606"],"confidence":"Medium","gaps":["Identity of the shed ligand(s) not pinned down","Generality beyond mammary epithelial cells untested"]},{"year":2004,"claim":"Demonstrated EGFR kinase activity is required for hormone-driven cancer cell proliferation and survival, establishing cross-talk with androgen signaling.","evidence":"ErbB1 kinase inhibitors (CGP59326, PKI166), proliferation/apoptosis assays, and receptor-level Westerns in LNCaP prostate cancer cells","pmids":["12746839"],"confidence":"Medium","gaps":["Mechanism by which androgens raise surface ErbB1 unknown","Direct vs indirect coupling to androgen receptor not resolved"]},{"year":2004,"claim":"Established a physiological neuroendocrine role for glial EGFR in controlling LHRH secretion and reproduction.","evidence":"Genetic double-mutant mouse epistasis (Waved-2 plus astrocyte dominant-negative erbB-4), PGE2 production and LHRH-release assays","pmids":["15591145"],"confidence":"Medium","gaps":["Molecular link from astrocyte EGFR to PGE2 output incomplete","Relative contributions of erbB-1 vs erbB-4 not separated"]},{"year":2006,"claim":"Revealed that the deubiquitinase UBPY/USP8 paradoxically promotes EGFR degradation, refining the ubiquitin-control logic of receptor turnover.","evidence":"Co-IP, three dominant-negative UBPY constructs, and ubiquitination assays in NIH3T3/HEK293 cells","pmids":["17121848"],"confidence":"Medium","gaps":["Direct DUB substrate (receptor vs ESCRT machinery) not distinguished","Single-lab dominant-negative approach"]},{"year":2008,"claim":"Characterized EGFR ectodomain shedding and exosomal secretion as kinase-dependent routes for receptor export, expanding EGFR fate beyond degradation.","evidence":"Exosome isolation, GM6001 and AG1478 inhibitor treatments, Western blotting of conditioned-medium fractions","pmids":["17910038"],"confidence":"Medium","gaps":["Functional role of secreted/shed species not established","Responsible sheddase not identified"]},{"year":2008,"claim":"Identified ARAP1 as an endosomal trafficking regulator that slows EGFR progression to early endosomes and degradation, tuning ERK/JNK output.","evidence":"siRNA knockdown, co-localization microscopy with Rab5/EEA1, and ERK/JNK phosphorylation assays","pmids":["18939958"],"confidence":"Medium","gaps":["GAP activity requirement for ARAP1 function not tested","Reciprocal validation of EGFR-dependent ARAP1 recruitment limited"]},{"year":2008,"claim":"Showed adult cardiac function depends on cardiomyocyte EGFR signaling, defining a homeostatic role in the heart.","evidence":"Inducible cardiomyocyte-specific dominant-negative ErbB-1, echocardiography, histology, and receptor-phosphorylation Westerns in mice","pmids":["18599591"],"confidence":"Medium","gaps":["Downstream effector pathway from cardiac EGFR not defined","Rescue by adenylyl cyclase activator mechanism unexplained"]},{"year":2009,"claim":"Separated EGFR and ERBB2 contributions to metastasis, assigning EGFR to motility/invasion and ERBB2 to intravasation.","evidence":"In vivo intravital imaging in mouse mammary tumors with selective inhibitors (gefitinib, AG825)","pmids":["19458057"],"confidence":"Medium","gaps":["Molecular effectors driving the invasion step not identified","Single-lab in vivo imaging system"]},{"year":2010,"claim":"Identified cytohesins as cytoplasmic conformational activators of EGFR, providing a mechanism for kinase-domain activation downstream of dimerization.","evidence":"Cell-free reconstitution of cytohesin-dependent autophosphorylation, anisotropy microscopy of EGFR conformation, and in vivo proliferation assays","pmids":["20946980"],"confidence":"High","gaps":["Structural detail of cytohesin-induced rearrangement not resolved","Specificity across ErbB family members not fully mapped"]},{"year":2011,"claim":"Quantified how ligand binding and cortical actin stabilize signaling-competent EGFR dimers independently of kinase activity, linking membrane dynamics to activation.","evidence":"Two-color quantum-dot single-particle tracking with hidden Markov modeling, kinase inhibition, and actin disruption in living cells","pmids":["22020299"],"confidence":"High","gaps":["Identity of the actin-coupling factor not determined","Relation of dimer lifetime to downstream signal strength not quantified"]},{"year":2013,"claim":"Established DYRK1A as a positive regulator of EGFR stability driving glioblastoma stem-cell self-renewal.","evidence":"DYRK1A pharmacological inhibition, EGFR degradation assays, and in vivo tumor burden in primary GBM lines and neural progenitors","pmids":["23635774"],"confidence":"Medium","gaps":["Whether DYRK1A acts directly on EGFR or via trafficking machinery unknown","Phosphosite mediating stabilization not identified"]},{"year":2013,"claim":"Linked direct ErbB1-integrin-β1 heteroassociation to Akt-driven radioresistance in glioblastoma.","evidence":"Acceptor-photobleaching FRET on clinical sections and glioma lines, ectopic ErbB1 expression, and PI3K-inhibitor rescue","pmids":["23595626"],"confidence":"Medium","gaps":["Structural interface of the heterocomplex undefined","Causality between heteroassociation and Akt activation correlative"]},{"year":2015,"claim":"Showed EGFR sialylation state modulates activation, with NEU3 desialylation enhancing phosphorylation without altering receptor levels.","evidence":"Co-IP, wild-type vs catalytically inactive NEU3 comparison, Western blot, and mass spectrometry of EGFR glycosylation","pmids":["25922362"],"confidence":"Medium","gaps":["Specific glycosites controlling activation not mapped","Single-lab study without in vivo validation"]},{"year":2018,"claim":"Demonstrated that ERBB/EGFR activity is required to amplify RAS signaling and initiate KRAS-mutant lung tumors, defining a therapeutic dependency.","evidence":"Autochthonous KRASG12D mouse lung-tumor model with multi-ERBB and MEK inhibitor treatment plus in vitro proliferation","pmids":["29925636"],"confidence":"Medium","gaps":["Relative contribution of EGFR vs other ERBB members not isolated","Source of activating ligand in the tumor microenvironment unclear"]},{"year":2018,"claim":"Identified USP22 as a late-endosomal deubiquitinase that promotes EGFR recycling and sustains downstream signaling, driving TKI resistance.","evidence":"USP22 knockdown/overexpression, ubiquitination, degradation/recycling, and downstream signaling (STAT3, AKT/mTOR, MEK/ERK) assays with in vivo resistance models","pmids":["29981430"],"confidence":"Medium","gaps":["Direct USP22-EGFR contact vs indirect action not distinguished","How USP22 is recruited to late endosomes unknown"]},{"year":2021,"claim":"Defined the FBXL2-Grp94 axis as a proteasomal control point for EGFR (including TKI-resistant mutants) stability in NSCLC.","evidence":"Reciprocal Co-IP, proteasome-inhibitor assays, FBXL2 and Grp94 perturbation, and in vivo NSCLC growth assays","pmids":["34635651"],"confidence":"High","gaps":["Degron recognized by FBXL2 on EGFR not mapped","How Grp94 sterically blocks FBXL2 binding structurally undefined"]},{"year":2022,"claim":"Resolved how ligand status switches EGFR between opposing invasion programs in EGFR-amplified glioblastoma.","evidence":"Orthotopic mouse GBM models, pathway-specific knockdowns, invasion assays, BIN3/DOCK7 analysis, and TCGA correlation","pmids":["35915159"],"confidence":"High","gaps":["Trigger determining constitutive vs ligand-activated state in tumors unclear","Generality beyond EGFR-amplified GBM untested"]},{"year":null,"claim":"How the dimer-, conformation-, glycosylation-, and trafficking-level control layers are integrated to set a single quantitative signaling output in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model relating dimer lifetime, endosomal location, and ubiquitin/DUB balance to output magnitude","Structural basis for partner- and ligand-specific phosphosite selection unresolved","Direct vs indirect substrate relationships for most regulators (DYRK1A, USP22, ARAP1) undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6,18]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,6]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[6]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,16]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,12]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2,5,11]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,16]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[2,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,10,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[17,18]}],"complexes":[],"partners":["GRB2","ARAP1","USP8","USP22","FBXL2","HSP90B1","NEU3","ITGB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P00533","full_name":"Epidermal growth factor receptor","aliases":["Proto-oncogene c-ErbB-1","Receptor tyrosine-protein kinase erbB-1"],"length_aa":1210,"mass_kda":134.3,"function":"Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:10805725, PubMed:27153536, PubMed:2790960, PubMed:35538033). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:12297049, PubMed:15611079, PubMed:17909029, PubMed:20837704, PubMed:27153536, PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity) Isoform 2 may act as an antagonist of EGF action (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P00533/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EGFR","classification":"Not Classified","n_dependent_lines":229,"n_total_lines":1208,"dependency_fraction":0.18956953642384106},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EGFR","total_profiled":1310},"omim":[{"mim_id":"621519","title":"SCAFFOLDING CK1-ANCHORING PROTEIN B; SACK1B","url":"https://www.omim.org/entry/621519"},{"mim_id":"621454","title":"MULTIVESICULAR BODY SUBUNIT 12B; MVB12B","url":"https://www.omim.org/entry/621454"},{"mim_id":"621453","title":"MULTIVESICULAR BODY SUBUNIT 12A; MVB12A","url":"https://www.omim.org/entry/621453"},{"mim_id":"621301","title":"PROLINE-RICH COILED-COIL PROTEIN 1; PRRC1","url":"https://www.omim.org/entry/621301"},{"mim_id":"621164","title":"POLYCYSTIC KIDNEY DISEASE 9, SUSCEPTIBILITY TO; PKD9","url":"https://www.omim.org/entry/621164"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cell Junctions","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":61.8}],"url":"https://www.proteinatlas.org/search/EGFR"},"hgnc":{"alias_symbol":["ERBB1","ERRP"],"prev_symbol":["ERBB"]},"alphafold":{"accession":"P00533","domains":[{"cath_id":"3.80.20.20","chopping":"31-207","consensus_level":"high","plddt":92.0079,"start":31,"end":207},{"cath_id":"3.30.200.20","chopping":"703-793","consensus_level":"medium","plddt":76.7166,"start":703,"end":793},{"cath_id":"1.10.510.10","chopping":"796-989","consensus_level":"medium","plddt":86.6981,"start":796,"end":989}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00533","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00533-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00533-F1-predicted_aligned_error_v6.png","plddt_mean":75.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EGFR","jax_strain_url":"https://www.jax.org/strain/search?query=EGFR"},"sequence":{"accession":"P00533","fasta_url":"https://rest.uniprot.org/uniprotkb/P00533.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00533/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00533"}},"corpus_meta":[{"pmid":"11252954","id":"PMC_11252954","title":"Untangling the ErbB signalling network.","date":"2001","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11252954","citation_count":5512,"is_preprint":false},{"pmid":"15864276","id":"PMC_15864276","title":"ERBB receptors and cancer: the complexity of targeted inhibitors.","date":"2005","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15864276","citation_count":2642,"is_preprint":false},{"pmid":"19208461","id":"PMC_19208461","title":"ErbB receptors and signaling pathways in cancer.","date":"2009","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19208461","citation_count":762,"is_preprint":false},{"pmid":"12648469","id":"PMC_12648469","title":"The ErbB receptors and their role in cancer progression.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648469","citation_count":493,"is_preprint":false},{"pmid":"12648465","id":"PMC_12648465","title":"The deaf and the dumb: the biology of ErbB-2 and ErbB-3.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648465","citation_count":469,"is_preprint":false},{"pmid":"17671639","id":"PMC_17671639","title":"ErbB receptors: from oncogenes to targeted cancer therapies.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17671639","citation_count":446,"is_preprint":false},{"pmid":"32124699","id":"PMC_32124699","title":"Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.","date":"2020","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32124699","citation_count":421,"is_preprint":false},{"pmid":"9496384","id":"PMC_9496384","title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.","date":"1997","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9496384","citation_count":416,"is_preprint":false},{"pmid":"30500458","id":"PMC_30500458","title":"Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30500458","citation_count":377,"is_preprint":false},{"pmid":"28791631","id":"PMC_28791631","title":"ErbB Receptors and Cancer.","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28791631","citation_count":347,"is_preprint":false},{"pmid":"14967450","id":"PMC_14967450","title":"Signal transduction and oncogenesis by ErbB/HER receptors.","date":"2004","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/14967450","citation_count":308,"is_preprint":false},{"pmid":"17085050","id":"PMC_17085050","title":"ErbB receptors: new insights on mechanisms and biology.","date":"2006","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17085050","citation_count":292,"is_preprint":false},{"pmid":"12648467","id":"PMC_12648467","title":"Trafficking of the ErbB receptors and its influence on signaling.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648467","citation_count":289,"is_preprint":false},{"pmid":"33462501","id":"PMC_33462501","title":"Antitumour immunity regulated by aberrant ERBB family signalling.","date":"2021","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33462501","citation_count":227,"is_preprint":false},{"pmid":"15857286","id":"PMC_15857286","title":"The ErbB receptors and their ligands in cancer: an overview.","date":"2005","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/15857286","citation_count":221,"is_preprint":false},{"pmid":"17432114","id":"PMC_17432114","title":"The neuregulin-I/ErbB signaling system in development and disease.","date":"2007","source":"Advances in anatomy, embryology, and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17432114","citation_count":221,"is_preprint":false},{"pmid":"22020299","id":"PMC_22020299","title":"ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding.","date":"2011","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22020299","citation_count":215,"is_preprint":false},{"pmid":"15163842","id":"PMC_15163842","title":"Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.","date":"2004","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/15163842","citation_count":212,"is_preprint":false},{"pmid":"9710588","id":"PMC_9710588","title":"ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9710588","citation_count":210,"is_preprint":false},{"pmid":"12648466","id":"PMC_12648466","title":"ErbB-4: mechanism of action and biology.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648466","citation_count":194,"is_preprint":false},{"pmid":"8098013","id":"PMC_8098013","title":"Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas.","date":"1993","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8098013","citation_count":187,"is_preprint":false},{"pmid":"12648471","id":"PMC_12648471","title":"ErbB-targeted therapeutic approaches in human cancer.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12648471","citation_count":181,"is_preprint":false},{"pmid":"19038249","id":"PMC_19038249","title":"Ligand-induced ErbB receptor dimerization.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19038249","citation_count":173,"is_preprint":false},{"pmid":"2565604","id":"PMC_2565604","title":"The neu (c-erbB-2) oncogene.","date":"1989","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/2565604","citation_count":142,"is_preprint":false},{"pmid":"17208435","id":"PMC_17208435","title":"Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).","date":"2007","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/17208435","citation_count":135,"is_preprint":false},{"pmid":"17121848","id":"PMC_17121848","title":"UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17121848","citation_count":120,"is_preprint":false},{"pmid":"24216225","id":"PMC_24216225","title":"Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).","date":"2013","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24216225","citation_count":116,"is_preprint":false},{"pmid":"11566606","id":"PMC_11566606","title":"The ErbB receptor tyrosine family as signal integrators.","date":"2001","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11566606","citation_count":116,"is_preprint":false},{"pmid":"23635774","id":"PMC_23635774","title":"Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23635774","citation_count":111,"is_preprint":false},{"pmid":"33325513","id":"PMC_33325513","title":"Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity.","date":"2021","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33325513","citation_count":106,"is_preprint":false},{"pmid":"12612606","id":"PMC_12612606","title":"Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.","date":"2003","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12612606","citation_count":102,"is_preprint":false},{"pmid":"7905269","id":"PMC_7905269","title":"neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer.","date":"1993","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7905269","citation_count":97,"is_preprint":false},{"pmid":"16460914","id":"PMC_16460914","title":"Signaling through ERBB receptors: multiple layers of diversity and control.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16460914","citation_count":96,"is_preprint":false},{"pmid":"29925636","id":"PMC_29925636","title":"The ERBB network facilitates KRAS-driven lung tumorigenesis.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29925636","citation_count":95,"is_preprint":false},{"pmid":"12947392","id":"PMC_12947392","title":"ERBB receptor tyrosine kinases and cellular radiation responses.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12947392","citation_count":95,"is_preprint":false},{"pmid":"17910038","id":"PMC_17910038","title":"Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17910038","citation_count":95,"is_preprint":false},{"pmid":"29371993","id":"PMC_29371993","title":"Genomic alterations of ERBB receptors in cancer: clinical implications.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29371993","citation_count":91,"is_preprint":false},{"pmid":"23506556","id":"PMC_23506556","title":"Diarrhea associated with afatinib: an oral ErbB family blocker.","date":"2013","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23506556","citation_count":87,"is_preprint":false},{"pmid":"11999214","id":"PMC_11999214","title":"The EGF/ErbB receptor family and apoptosis.","date":"2002","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/11999214","citation_count":85,"is_preprint":false},{"pmid":"9546426","id":"PMC_9546426","title":"The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9546426","citation_count":79,"is_preprint":false},{"pmid":"16741920","id":"PMC_16741920","title":"Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence.","date":"2006","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16741920","citation_count":78,"is_preprint":false},{"pmid":"18992239","id":"PMC_18992239","title":"Interaction of antibodies with ErbB receptor extracellular regions.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18992239","citation_count":75,"is_preprint":false},{"pmid":"10824084","id":"PMC_10824084","title":"Evolutionary analysis of the ErbB receptor and ligand families.","date":"2000","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/10824084","citation_count":75,"is_preprint":false},{"pmid":"19124237","id":"PMC_19124237","title":"Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.","date":"2009","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/19124237","citation_count":73,"is_preprint":false},{"pmid":"16729016","id":"PMC_16729016","title":"Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16729016","citation_count":72,"is_preprint":false},{"pmid":"20933094","id":"PMC_20933094","title":"ErbB signaling in cardiac development and disease.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20933094","citation_count":71,"is_preprint":false},{"pmid":"21816844","id":"PMC_21816844","title":"Targeting the HER/EGFR/ErbB family to prevent breast cancer.","date":"2011","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/21816844","citation_count":70,"is_preprint":false},{"pmid":"12138392","id":"PMC_12138392","title":"HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.","date":"2002","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12138392","citation_count":70,"is_preprint":false},{"pmid":"25336113","id":"PMC_25336113","title":"SOX9 regulates ERBB signalling in pancreatic cancer development.","date":"2014","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/25336113","citation_count":70,"is_preprint":false},{"pmid":"24381541","id":"PMC_24381541","title":"The role of EGFR and ErbB family related proteins in the oligodendrocyte specification in germinal niches of the adult mammalian brain.","date":"2013","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24381541","citation_count":69,"is_preprint":false},{"pmid":"16719802","id":"PMC_16719802","title":"Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.","date":"2006","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16719802","citation_count":68,"is_preprint":false},{"pmid":"17311611","id":"PMC_17311611","title":"New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.","date":"2007","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/17311611","citation_count":67,"is_preprint":false},{"pmid":"19013149","id":"PMC_19013149","title":"The role of protease activity in ErbB biology.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19013149","citation_count":63,"is_preprint":false},{"pmid":"15591145","id":"PMC_15591145","title":"erbB-1 and erbB-4 receptors act in concert to facilitate female sexual development and mature reproductive function.","date":"2004","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15591145","citation_count":61,"is_preprint":false},{"pmid":"20946980","id":"PMC_20946980","title":"Cytohesins are cytoplasmic ErbB receptor activators.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20946980","citation_count":59,"is_preprint":false},{"pmid":"12846405","id":"PMC_12846405","title":"Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours.","date":"2003","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/12846405","citation_count":58,"is_preprint":false},{"pmid":"16533841","id":"PMC_16533841","title":"Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.","date":"2006","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16533841","citation_count":57,"is_preprint":false},{"pmid":"21917845","id":"PMC_21917845","title":"Expression and function of ErbB receptors and ligands in the pituitary.","date":"2011","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21917845","citation_count":56,"is_preprint":false},{"pmid":"17525275","id":"PMC_17525275","title":"Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17525275","citation_count":55,"is_preprint":false},{"pmid":"11807621","id":"PMC_11807621","title":"Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.","date":"2001","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/11807621","citation_count":55,"is_preprint":false},{"pmid":"34635651","id":"PMC_34635651","title":"FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34635651","citation_count":54,"is_preprint":false},{"pmid":"28522156","id":"PMC_28522156","title":"The Role of ErbB Receptors in Infection.","date":"2017","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28522156","citation_count":52,"is_preprint":false},{"pmid":"29981430","id":"PMC_29981430","title":"USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29981430","citation_count":52,"is_preprint":false},{"pmid":"12845622","id":"PMC_12845622","title":"c-erbB-4/HER4: friend or foe?","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12845622","citation_count":51,"is_preprint":false},{"pmid":"11248544","id":"PMC_11248544","title":"Localization and modulation of ErbB receptor tyrosine kinases.","date":"2001","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11248544","citation_count":48,"is_preprint":false},{"pmid":"14641025","id":"PMC_14641025","title":"Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling.","date":"2003","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/14641025","citation_count":47,"is_preprint":false},{"pmid":"25922362","id":"PMC_25922362","title":"NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.","date":"2015","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25922362","citation_count":47,"is_preprint":false},{"pmid":"31083325","id":"PMC_31083325","title":"Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31083325","citation_count":46,"is_preprint":false},{"pmid":"17044774","id":"PMC_17044774","title":"Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells.","date":"2006","source":"Nutrition and cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17044774","citation_count":44,"is_preprint":false},{"pmid":"28235789","id":"PMC_28235789","title":"ERBB signaling attenuates proinflammatory activation of nonclassical monocytes.","date":"2017","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28235789","citation_count":44,"is_preprint":false},{"pmid":"18939958","id":"PMC_18939958","title":"ARAP1 regulates endocytosis of EGFR.","date":"2008","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/18939958","citation_count":42,"is_preprint":false},{"pmid":"33033232","id":"PMC_33033232","title":"Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.","date":"2020","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33033232","citation_count":41,"is_preprint":false},{"pmid":"18585454","id":"PMC_18585454","title":"Effector mechanisms of therapeutic antibodies against ErbB receptors.","date":"2008","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18585454","citation_count":40,"is_preprint":false},{"pmid":"22587495","id":"PMC_22587495","title":"Quantification of differential ErbB1 and ErbB2 cell surface expression and spatial nanoclustering through plasmon coupling.","date":"2012","source":"Nano letters","url":"https://pubmed.ncbi.nlm.nih.gov/22587495","citation_count":39,"is_preprint":false},{"pmid":"32978523","id":"PMC_32978523","title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32978523","citation_count":39,"is_preprint":false},{"pmid":"12746839","id":"PMC_12746839","title":"ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.","date":"2003","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/12746839","citation_count":39,"is_preprint":false},{"pmid":"19458057","id":"PMC_19458057","title":"ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19458057","citation_count":38,"is_preprint":false},{"pmid":"20868762","id":"PMC_20868762","title":"E3 ubiquitin ligases in ErbB receptor quantity control.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20868762","citation_count":36,"is_preprint":false},{"pmid":"21827413","id":"PMC_21827413","title":"Targeting ErbB receptors in high-grade glioma.","date":"2011","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/21827413","citation_count":35,"is_preprint":false},{"pmid":"31496745","id":"PMC_31496745","title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31496745","citation_count":34,"is_preprint":false},{"pmid":"11668496","id":"PMC_11668496","title":"Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11668496","citation_count":34,"is_preprint":false},{"pmid":"35915159","id":"PMC_35915159","title":"EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35915159","citation_count":33,"is_preprint":false},{"pmid":"10882304","id":"PMC_10882304","title":"Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.","date":"1997","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/10882304","citation_count":33,"is_preprint":false},{"pmid":"34487971","id":"PMC_34487971","title":"The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.","date":"2021","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/34487971","citation_count":33,"is_preprint":false},{"pmid":"18599591","id":"PMC_18599591","title":"Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18599591","citation_count":33,"is_preprint":false},{"pmid":"16984691","id":"PMC_16984691","title":"ErbB receptors and their ligands in the breast.","date":"2006","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16984691","citation_count":32,"is_preprint":false},{"pmid":"11102970","id":"PMC_11102970","title":"Neuregulins and erbB receptor expression in adult human oligodendrocytes.","date":"2000","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/11102970","citation_count":31,"is_preprint":false},{"pmid":"19305165","id":"PMC_19305165","title":"MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19305165","citation_count":31,"is_preprint":false},{"pmid":"26163475","id":"PMC_26163475","title":"Targeting HER (ERBB) signaling in head and neck cancer: An essential update.","date":"2015","source":"Molecular aspects of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26163475","citation_count":30,"is_preprint":false},{"pmid":"21920801","id":"PMC_21920801","title":"Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.","date":"2011","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/21920801","citation_count":29,"is_preprint":false},{"pmid":"23595626","id":"PMC_23595626","title":"Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.","date":"2013","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23595626","citation_count":29,"is_preprint":false},{"pmid":"24802673","id":"PMC_24802673","title":"A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.","date":"2014","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/24802673","citation_count":28,"is_preprint":false},{"pmid":"25699077","id":"PMC_25699077","title":"ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.","date":"2015","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25699077","citation_count":28,"is_preprint":false},{"pmid":"33210573","id":"PMC_33210573","title":"EGFR and anti-EGFR nanobodies: review and update.","date":"2020","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/33210573","citation_count":27,"is_preprint":false},{"pmid":"15163843","id":"PMC_15163843","title":"The role of ErbB inhibitors in trastuzumab resistance.","date":"2004","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/15163843","citation_count":27,"is_preprint":false},{"pmid":"20850557","id":"PMC_20850557","title":"Targeting erbB receptors.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20850557","citation_count":25,"is_preprint":false},{"pmid":"32708604","id":"PMC_32708604","title":"ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32708604","citation_count":25,"is_preprint":false},{"pmid":"31613219","id":"PMC_31613219","title":"Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31613219","citation_count":25,"is_preprint":false},{"pmid":"24370847","id":"PMC_24370847","title":"The spatiotemporal organization of ErbB receptors: insights from microscopy.","date":"2014","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/24370847","citation_count":25,"is_preprint":false},{"pmid":"12409827","id":"PMC_12409827","title":"Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma.","date":"2002","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/12409827","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45007,"output_tokens":5619,"usd":0.109653,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14142,"output_tokens":5809,"usd":0.107967,"stage2_stop_reason":"end_turn"},"total_usd":0.21762,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"ErbB1 (EGFR) acquires distinct signaling properties depending on its dimerization partner: EGF-activated ErbB-1 interacts with Grb2 and undergoes rapid internalization with biphasic PI3-K association, whereas NDF-activated ErbB-1 (via ErbB-4 heterodimerization) cannot interact with Grb2 and shows delayed internalization with monophasic PI3-K association. Tryptic phosphopeptide mapping confirmed that receptor phosphorylation patterns are dependent on the dimerization partner.\",\n      \"method\": \"Co-immunoprecipitation, phosphopeptide mapping, internalization assays in NIH 3T3 cells expressing defined receptor combinations\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, phosphopeptide mapping, and internalization assays; multiple orthogonal methods in a single focused study\",\n      \"pmids\": [\"9710588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"At high concentrations, EGF and betacellulin can activate the ErbB-2/ErbB-3 heterodimer as a surrogate receptor in the absence of ErbB-1; the middle portion of EGF (loop B) was identified as the structural determinant enabling activation of the ErbB-2/ErbB-3 complex.\",\n      \"method\": \"Cell growth/differentiation assays with site-specific antibody blockade, EGF/TGFα chimera analysis in cells expressing defined receptor combinations\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (antibody blockade, chimeric ligand mapping, defined receptor expression systems) in a single study\",\n      \"pmids\": [\"9546426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EGFR (ErbB1) trafficking is uniquely ligand-regulated among ErbB family members: upon EGF binding, EGFR undergoes accelerated internalization and enhanced lysosomal targeting (rather than recycling), mediated by cytoplasmic domain motifs exposed by activation-induced conformational changes and Grb2 binding. Most EGFR signaling consequently occurs within endosomes.\",\n      \"method\": \"Receptor trafficking assays, receptor internalization rate measurements, domain mutant analysis, Grb2-binding studies\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection of trafficking motifs and Grb2 involvement, primarily review synthesizing experimental data from multiple labs\",\n      \"pmids\": [\"12648467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"UBPY (Usp8) constitutively co-precipitates with EGFR in a bivalent manner and is a substrate for Src-family tyrosine kinases activated by ligand-induced EGFR activation. Dominant-negative UBPY mutants demonstrate that UBPY-mediated deubiquitination promotes (rather than inhibits) EGFR degradation, and affects both constitutive and ligand-induced EGFR ubiquitination, expression levels, and MAPK signaling.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative UBPY mutant overexpression, ubiquitination assays in NIH3T3 and HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus multiple dominant-negative mutants (three independent constructs), single lab\",\n      \"pmids\": [\"17121848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EGFR (ErbB1) can undergo metalloprotease-dependent ectodomain shedding to generate soluble N-terminal ectodomains (which retain ligand-binding ability) and membrane-associated C-terminal remnant fragments; full-length transmembrane ErbB1 is also secreted in exosomes. Ligand-stimulated ErbB1 secretion into exosomes requires ErbB1 kinase activity, as it is blocked by the kinase inhibitor AG1478.\",\n      \"method\": \"Exosome isolation, metalloprotease inhibitor treatments (GM6001), kinase inhibitor (AG1478) treatment, Western blotting of conditioned medium fractions\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical fractionation with pharmacological inhibitors, single lab, two orthogonal methods\",\n      \"pmids\": [\"17910038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1 (an Arf GAP/Rho GAP domain protein) regulates EGFR endocytic trafficking: after EGF treatment, ARAP1 transiently associates with Rab5-positive punctate structures containing EGFR prior to EEA1-positive early endosomes; ARAP1 recruitment requires active Rab5 and a signal from EGFR. siRNA knockdown of ARAP1 accelerated EGFR association with EEA1 endosomes and EGFR degradation, and diminished ERK and JNK phosphorylation.\",\n      \"method\": \"siRNA knockdown, fluorescence microscopy, co-localization with endosomal markers, ERK/JNK phosphorylation assays\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with defined cellular phenotype, co-localization microscopy, signaling readouts; single lab\",\n      \"pmids\": [\"18939958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cytohesin family proteins are cytoplasmic activators of ErbB receptors including EGFR: cytohesin inhibition decreased EGFR autophosphorylation and downstream signaling, while cytohesin overexpression stimulated receptor activation. Cell-free reconstitution of cytohesin-dependent EGFR autophosphorylation and anisotropy microscopy monitoring of EGFR conformation indicated cytohesins facilitate conformational rearrangements in intracellular domains of dimerized receptors.\",\n      \"method\": \"Cell-free reconstitution assay, anisotropy microscopy (EGFR conformation monitoring), cytohesin overexpression/inhibition, in vitro and in vivo proliferation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-free reconstitution plus anisotropy microscopy and in vivo validation; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"20946980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ErbB1 (EGFR) dimerization is promoted by transient co-confinement of receptors and stabilized by ligand binding: two-color quantum-dot tracking revealed that dimers of two ligand-bound receptors are long-lived (>4-fold slower dimer off-rate than unliganded dimers) and dimer off-rate is independent of kinase activity. Blockade of kinase activity or disruption of actin networks results in faster diffusion of receptor dimers, implicating cortical cytoskeleton in reduced mobility of signaling-competent dimers.\",\n      \"method\": \"Two-color quantum-dot single-particle tracking, hidden Markov model analysis of dimer kinetics, kinase inhibitors, actin network disruption in living cells\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative single-molecule live-cell imaging with rigorous kinetic modeling and pharmacological validation, multiple orthogonal perturbations\",\n      \"pmids\": [\"22020299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DYRK1A kinase regulates EGFR stability in glioblastoma: DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, reducing self-renewal capacity. This establishes DYRK1A as a positive regulator of surface EGFR levels, and DYRK1A-dependent EGFR stabilization as a key oncogenic mechanism in a subset of GBMs.\",\n      \"method\": \"DYRK1A pharmacological inhibition, EGFR degradation assays, primary GBM cell lines, in vivo tumor burden assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with cellular and in vivo phenotype, single lab, multiple readouts\",\n      \"pmids\": [\"23635774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EGFR (ERBB1) activity is required for KRAS-driven lung tumor initiation and progression: multiple ERBB RTKs are expressed and active from the earliest stages of KRASG12D-driven lung tumor development, and multi-ERBB inhibition suppresses formation of these tumors. ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells.\",\n      \"method\": \"Autochthonous mouse lung tumor model (KRASG12D), multi-ERBB inhibitor treatment, MEK inhibitor combination, in vitro proliferation assays\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in autochthonous mouse model plus in vitro signaling studies; single lab with multiple experimental approaches\",\n      \"pmids\": [\"29925636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FBXL2 (an F-box protein) targets EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation. Grp94 protects EGFR from FBXL2-mediated degradation by blocking FBXL2 binding to EGFR. The FBXL2-Grp94-EGFR axis controls EGFR protein stability in NSCLC.\",\n      \"method\": \"Co-immunoprecipitation, proteasome inhibitor assays, FBXL2 knockdown/overexpression, Grp94 inhibition, in vitro and in vivo NSCLC growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP establishing FBXL2-EGFR and Grp94-EGFR interactions, proteasomal degradation assays, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"34635651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"USP22 deubiquitinates EGFR localized on late endosomes, prevents ubiquitination-mediated EGFR degradation, and enhances EGFR recycling after EGF stimulation, thereby sustaining activation of EGFR downstream signaling pathways (STAT3, AKT/mTOR, MEK/ERK) and promoting resistance to EGFR-TKIs.\",\n      \"method\": \"USP22 knockdown/overexpression, ubiquitination assays, EGFR degradation and recycling assays, downstream signaling analysis, in vitro and in vivo resistance assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic deubiquitination assay with trafficking and signaling readouts; single lab, multiple methods\",\n      \"pmids\": [\"29981430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The plasma membrane sialidase NEU3 co-immunoprecipitates with EGFR and, when catalytically active, enhances EGFR activation (phosphorylation) without affecting EGFR mRNA or protein expression levels. Active NEU3 desialylates immunoprecipitated EGFR, as confirmed by Western blot and mass spectrometry, suggesting EGFR sialylation status modulates its activation.\",\n      \"method\": \"Co-immunoprecipitation, overexpression of wild-type vs. catalytically inactive NEU3 mutant, Western blot, mass spectrometry of EGFR glycosylation\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus mass spectrometry-confirmed desialylation, wild-type vs. inactive mutant comparison; single lab\",\n      \"pmids\": [\"25922362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Wnt1 and Wnt5a transactivate ErbB1 (EGFR) in HC11 mammary epithelial cells via metalloprotease-mediated release of soluble ErbB1 ligands downstream of Frizzled receptor activation. ErbB1 transactivation by Wnt was required for MAPK activation and cyclin D1 upregulation in Wnt-expressing cells.\",\n      \"method\": \"Conditioned medium transfer assays, ErbB1-blocking antibody, MMP inhibitors, MAPK and cyclin D1 measurements in HC11 cells\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody blockade and MMP inhibitor rescue experiments establish pathway epistasis; single lab, multiple inhibitor approaches\",\n      \"pmids\": [\"12612606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ErbB-1 (EGFR) kinase activity is essential for androgen-induced proliferation and survival of LNCaP prostate cancer cells: androgens increase ErbB1 surface levels while decreasing ErbB2 levels, and ErbB1 kinase inhibitors (CGP59326, PKI166) completely block androgen-induced proliferation and prevent androgen-mediated rescue from PI3K inhibitor-induced apoptosis.\",\n      \"method\": \"ErbB1 tyrosine kinase inhibitors (CGP59326, PKI166), LNCaP cell proliferation and apoptosis assays, Western blotting of receptor levels\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with proliferation and apoptosis phenotype; single lab, two inhibitors tested\",\n      \"pmids\": [\"12746839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERBB1 (EGFR) inhibition specifically blocks tumor cell motility and invasion in vivo, while ERBB2 inhibition specifically blocks intravasation, distinguishing the contributions of each receptor to distinct steps of metastasis. ERBB1 inhibition (gefitinib) rapidly (within 3 h) inhibits invasion but not intravasation, whereas ERBB2 inhibition blocks intravasation.\",\n      \"method\": \"In vivo mouse mammary tumor models, intravital imaging of tumor cell motility and intravasation, selective small-molecule inhibitors (gefitinib for ERBB1, AG825 for ERBB2)\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo intravital imaging with selective inhibitors distinguishing EGFR vs ERBB2 roles; single lab\",\n      \"pmids\": [\"19458057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Constitutive (ligand-independent) EGFR signaling promotes glioblastoma invasion via a TAB1-TAK1-NF-κB-EMP1 pathway, while ligand-activated EGFR suppresses invasion by upregulating BIN3, which inhibits a DOCK7-regulated Rho GTPase pathway. Ligand binding thus shifts EGFR from an invasion-promoting to an invasion-suppressing role in EGFR-amplified GBM.\",\n      \"method\": \"Orthotopic mouse GBM models, pathway-specific knockdowns, in vitro invasion assays, BIN3/DOCK7 pathway analysis, TCGA data correlation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo orthotopic models with mechanistic pathway dissection, multiple genetic perturbations, and clinical data correlation; multiple orthogonal methods\",\n      \"pmids\": [\"35915159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Glial erbB-1 and erbB-4 receptors work in a coordinated fashion to control LHRH secretion and reproductive function: double-mutant mice (Waved-2 erbB-1 point mutation plus dominant-negative erbB-4 in astrocytes) show further delayed puberty and diminished reproductive capacity compared to single mutants. Mutant astrocytes fail to produce prostaglandin E2 in response to TGFα, and conditioned medium from mutant astrocytes fails to stimulate LHRH release.\",\n      \"method\": \"Genetic epistasis (double-mutant mouse crosses), astrocyte prostaglandin E2 production assays, LHRH release assay from GT1-7 cells, LH response to ovariectomy\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic double-mutant epistasis with cellular mechanistic readouts; single publication\",\n      \"pmids\": [\"15591145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cardiac ErbB-1 (EGFR) signaling is required for adult cardiac function: cardiomyocyte-specific expression of dominant-negative ErbB-1 mutant blocked endogenous ErbB-1 phosphorylation and ErbB-2 transphosphorylation, leading to cardiac hypertrophy, dilation, and dysfunction (decreased fractional shortening). Cardiac function was normalized by adenylyl cyclase activator treatment and reversed upon cessation of mutant expression.\",\n      \"method\": \"Ecdysone-inducible cardiomyocyte-specific dominant-negative ErbB-1 mutant expression, echocardiography, histology, Western blotting of receptor phosphorylation\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible dominant-negative in vivo mouse model with molecular and physiological readouts; single lab\",\n      \"pmids\": [\"18599591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ErbB1-integrin-β1 physical heteroassociation (measured by FRET) in glioblastoma correlates with radioresistance: ectopic ErbB1 expression upregulated integrin-β1 and increased ErbB1-integrin-β1 heteroassociation, boosting Akt phosphorylation in response to EGF. Radioresistance could be reverted by PI3K inhibition, establishing ErbB1-integrin-β1 interaction as a driver of Akt-mediated radioresistance.\",\n      \"method\": \"Acceptor photobleaching FRET on clinical frozen sections and in vitro glioma cell lines, ErbB1 ectopic expression, PI3K inhibitor rescue, Akt phosphorylation assays\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET-based direct interaction measurement plus functional rescue with PI3K inhibitor; single lab\",\n      \"pmids\": [\"23595626\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EGFR (ErbB1) is a ligand-activated receptor tyrosine kinase whose activity, signaling output, and fate are controlled by a multilayered network: ligand binding drives homo- or heterodimerization (with distinct dimer-dependent phosphorylation patterns and signaling properties), cytoplasmic conformational activators (cytohesins) facilitate kinase domain activation, ligand-occupied dimers are stabilized by co-confinement and cortical actin interactions, activated receptor undergoes accelerated clathrin-mediated internalization and lysosomal targeting (regulated by ubiquitination/deubiquitination via UBPY/USP22/FBXL2-Grp94 and trafficking regulators such as ARAP1), and constitutive vs. ligand-activated EGFR signaling can engage distinct downstream pathways (e.g., TAB1-TAK1-NF-κB-EMP1 for invasion vs. BIN3-DOCK7 for invasion suppression), with additional modulation by sialylation state, transactivation by GPCRs and Wnt via metalloprotease-dependent ligand shedding, and stabilization/destabilization by kinases such as DYRK1A.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EGFR (ErbB1) is a ligand-activated receptor tyrosine kinase whose signaling output, trafficking, and physiological fate are shaped by its dimerization state, conformational regulators, and the route by which it is internalized and degraded [#0, #6]. Ligand binding determines both partner choice and downstream wiring: EGF-activated ErbB1 binds Grb2 and internalizes rapidly with biphasic PI3-K association, whereas heterodimerization with ErbB-4 yields a Grb2-incompetent receptor with delayed internalization and distinct phosphopeptide patterns [#0], and high-affinity ligands can drive ErbB-2/ErbB-3 surrogate signaling in the absence of ErbB1 [#1]. Receptor activation is facilitated by cytoplasmic cytohesins, which promote conformational rearrangement of the intracellular domains of dimerized receptors to enable autophosphorylation [#6], while signaling-competent dimers of two ligand-bound receptors are long-lived and stabilized by co-confinement and cortical actin [#7]. Activated EGFR is uniquely routed toward accelerated clathrin-mediated internalization and lysosomal degradation rather than recycling, so much of its signaling occurs from endosomes [#2]; this fate is tuned by trafficking and degradation machinery including ARAP1 at Rab5 endosomes [#5], the deubiquitinases UBPY/USP8 and USP22 [#3, #11], the FBXL2–Grp94 axis controlling proteasomal stability [#10], and the stabilizing kinase DYRK1A [#8]. Additional input comes from NEU3-mediated desialylation, which enhances EGFR phosphorylation without changing its expression [#12], and from transactivation by Wnt and other stimuli through metalloprotease-dependent shedding of soluble ligands [#13]. EGFR activity drives proliferation, survival, motility, and invasion across multiple tissue and tumor contexts, including KRAS-driven lung tumor initiation [#9], androgen-dependent prostate cancer growth [#14], and metastatic cell motility [#15]; in EGFR-amplified glioblastoma, constitutive signaling promotes invasion via TAB1-TAK1-NF-\\u03baB-EMP1 whereas ligand-activated EGFR suppresses invasion via BIN3-DOCK7 [#16]. EGFR also supports normal physiology, including astrocyte-mediated control of LHRH secretion [#17] and adult cardiac function [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that EGFR signaling identity is dimerization-partner-dependent rather than fixed, explaining how the same receptor produces divergent outputs.\",\n      \"evidence\": \"Co-IP, phosphopeptide mapping, and internalization assays in NIH 3T3 cells with defined receptor combinations; plus chimeric-ligand mapping of ErbB-2/ErbB-3 surrogate activation\",\n      \"pmids\": [\"9710588\", \"9546426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dimer-specific phosphosite selection not resolved\", \"Physiological ligand concentrations for surrogate ErbB-2/ErbB-3 activation unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined EGFR as uniquely ligand-routed to lysosomal degradation, reframing endosomes as a principal signaling compartment.\",\n      \"evidence\": \"Trafficking and internalization-rate assays, cytoplasmic-domain mutant analysis, and Grb2-binding studies (review synthesizing experimental data)\",\n      \"pmids\": [\"12648467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of endosomal vs surface signaling not partitioned\", \"Review-level synthesis rather than single primary dataset\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed EGFR can be transactivated by Wnt through metalloprotease-dependent ligand shedding, linking it to non-canonical upstream inputs.\",\n      \"evidence\": \"Conditioned-medium transfer, ErbB1-blocking antibody, and MMP inhibitors with MAPK/cyclin D1 readouts in HC11 mammary cells\",\n      \"pmids\": [\"12612606\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the shed ligand(s) not pinned down\", \"Generality beyond mammary epithelial cells untested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated EGFR kinase activity is required for hormone-driven cancer cell proliferation and survival, establishing cross-talk with androgen signaling.\",\n      \"evidence\": \"ErbB1 kinase inhibitors (CGP59326, PKI166), proliferation/apoptosis assays, and receptor-level Westerns in LNCaP prostate cancer cells\",\n      \"pmids\": [\"12746839\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which androgens raise surface ErbB1 unknown\", \"Direct vs indirect coupling to androgen receptor not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established a physiological neuroendocrine role for glial EGFR in controlling LHRH secretion and reproduction.\",\n      \"evidence\": \"Genetic double-mutant mouse epistasis (Waved-2 plus astrocyte dominant-negative erbB-4), PGE2 production and LHRH-release assays\",\n      \"pmids\": [\"15591145\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link from astrocyte EGFR to PGE2 output incomplete\", \"Relative contributions of erbB-1 vs erbB-4 not separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed that the deubiquitinase UBPY/USP8 paradoxically promotes EGFR degradation, refining the ubiquitin-control logic of receptor turnover.\",\n      \"evidence\": \"Co-IP, three dominant-negative UBPY constructs, and ubiquitination assays in NIH3T3/HEK293 cells\",\n      \"pmids\": [\"17121848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DUB substrate (receptor vs ESCRT machinery) not distinguished\", \"Single-lab dominant-negative approach\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Characterized EGFR ectodomain shedding and exosomal secretion as kinase-dependent routes for receptor export, expanding EGFR fate beyond degradation.\",\n      \"evidence\": \"Exosome isolation, GM6001 and AG1478 inhibitor treatments, Western blotting of conditioned-medium fractions\",\n      \"pmids\": [\"17910038\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of secreted/shed species not established\", \"Responsible sheddase not identified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified ARAP1 as an endosomal trafficking regulator that slows EGFR progression to early endosomes and degradation, tuning ERK/JNK output.\",\n      \"evidence\": \"siRNA knockdown, co-localization microscopy with Rab5/EEA1, and ERK/JNK phosphorylation assays\",\n      \"pmids\": [\"18939958\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GAP activity requirement for ARAP1 function not tested\", \"Reciprocal validation of EGFR-dependent ARAP1 recruitment limited\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed adult cardiac function depends on cardiomyocyte EGFR signaling, defining a homeostatic role in the heart.\",\n      \"evidence\": \"Inducible cardiomyocyte-specific dominant-negative ErbB-1, echocardiography, histology, and receptor-phosphorylation Westerns in mice\",\n      \"pmids\": [\"18599591\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream effector pathway from cardiac EGFR not defined\", \"Rescue by adenylyl cyclase activator mechanism unexplained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Separated EGFR and ERBB2 contributions to metastasis, assigning EGFR to motility/invasion and ERBB2 to intravasation.\",\n      \"evidence\": \"In vivo intravital imaging in mouse mammary tumors with selective inhibitors (gefitinib, AG825)\",\n      \"pmids\": [\"19458057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effectors driving the invasion step not identified\", \"Single-lab in vivo imaging system\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified cytohesins as cytoplasmic conformational activators of EGFR, providing a mechanism for kinase-domain activation downstream of dimerization.\",\n      \"evidence\": \"Cell-free reconstitution of cytohesin-dependent autophosphorylation, anisotropy microscopy of EGFR conformation, and in vivo proliferation assays\",\n      \"pmids\": [\"20946980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of cytohesin-induced rearrangement not resolved\", \"Specificity across ErbB family members not fully mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Quantified how ligand binding and cortical actin stabilize signaling-competent EGFR dimers independently of kinase activity, linking membrane dynamics to activation.\",\n      \"evidence\": \"Two-color quantum-dot single-particle tracking with hidden Markov modeling, kinase inhibition, and actin disruption in living cells\",\n      \"pmids\": [\"22020299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the actin-coupling factor not determined\", \"Relation of dimer lifetime to downstream signal strength not quantified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established DYRK1A as a positive regulator of EGFR stability driving glioblastoma stem-cell self-renewal.\",\n      \"evidence\": \"DYRK1A pharmacological inhibition, EGFR degradation assays, and in vivo tumor burden in primary GBM lines and neural progenitors\",\n      \"pmids\": [\"23635774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether DYRK1A acts directly on EGFR or via trafficking machinery unknown\", \"Phosphosite mediating stabilization not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked direct ErbB1-integrin-\\u03b21 heteroassociation to Akt-driven radioresistance in glioblastoma.\",\n      \"evidence\": \"Acceptor-photobleaching FRET on clinical sections and glioma lines, ectopic ErbB1 expression, and PI3K-inhibitor rescue\",\n      \"pmids\": [\"23595626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural interface of the heterocomplex undefined\", \"Causality between heteroassociation and Akt activation correlative\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed EGFR sialylation state modulates activation, with NEU3 desialylation enhancing phosphorylation without altering receptor levels.\",\n      \"evidence\": \"Co-IP, wild-type vs catalytically inactive NEU3 comparison, Western blot, and mass spectrometry of EGFR glycosylation\",\n      \"pmids\": [\"25922362\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific glycosites controlling activation not mapped\", \"Single-lab study without in vivo validation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that ERBB/EGFR activity is required to amplify RAS signaling and initiate KRAS-mutant lung tumors, defining a therapeutic dependency.\",\n      \"evidence\": \"Autochthonous KRASG12D mouse lung-tumor model with multi-ERBB and MEK inhibitor treatment plus in vitro proliferation\",\n      \"pmids\": [\"29925636\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of EGFR vs other ERBB members not isolated\", \"Source of activating ligand in the tumor microenvironment unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified USP22 as a late-endosomal deubiquitinase that promotes EGFR recycling and sustains downstream signaling, driving TKI resistance.\",\n      \"evidence\": \"USP22 knockdown/overexpression, ubiquitination, degradation/recycling, and downstream signaling (STAT3, AKT/mTOR, MEK/ERK) assays with in vivo resistance models\",\n      \"pmids\": [\"29981430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct USP22-EGFR contact vs indirect action not distinguished\", \"How USP22 is recruited to late endosomes unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the FBXL2-Grp94 axis as a proteasomal control point for EGFR (including TKI-resistant mutants) stability in NSCLC.\",\n      \"evidence\": \"Reciprocal Co-IP, proteasome-inhibitor assays, FBXL2 and Grp94 perturbation, and in vivo NSCLC growth assays\",\n      \"pmids\": [\"34635651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron recognized by FBXL2 on EGFR not mapped\", \"How Grp94 sterically blocks FBXL2 binding structurally undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved how ligand status switches EGFR between opposing invasion programs in EGFR-amplified glioblastoma.\",\n      \"evidence\": \"Orthotopic mouse GBM models, pathway-specific knockdowns, invasion assays, BIN3/DOCK7 analysis, and TCGA correlation\",\n      \"pmids\": [\"35915159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger determining constitutive vs ligand-activated state in tumors unclear\", \"Generality beyond EGFR-amplified GBM untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the dimer-, conformation-, glycosylation-, and trafficking-level control layers are integrated to set a single quantitative signaling output in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model relating dimer lifetime, endosomal location, and ubiquitin/DUB balance to output magnitude\", \"Structural basis for partner- and ligand-specific phosphosite selection unresolved\", \"Direct vs indirect substrate relationships for most regulators (DYRK1A, USP22, ARAP1) undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6, 18]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 16]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 12]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2, 5, 11]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 16]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 10, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GRB2\", \"ARAP1\", \"USP8\", \"USP22\", \"FBXL2\", \"HSP90B1\", \"NEU3\", \"ITGB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}